Therefore, expression changes of AHR, NR1I3 (CAR) and NR1I2 (PXR), their target genes CYP1A1, CYP1A2, CYP2B6 and CYP3A4, as well as some steatosis-related genes (ACOX1, ACOX2, CD36, FASN, MLXIPL, SCD and SREPF1) were investigated to examine if gene expression changes may be responsible for the potentiation of the steatotic effect by FDO. The gene discussed is MLXIPL; the disease is steatosis.